Synbiotic Supplementation With Heyndrickxia coagulans TBC169 Improves Chronic Constipation in Middle-Aged and Elderly

IF 3.7 3区生物学 Q2 BIOCHEMICAL RESEARCH METHODS

Biotechnology Journal Pub Date : 2026-06-02 DOI:10.1002/biot.70250

Xiaoni Zhou, Canhui Guo, Gang Hu, Leiping Ding, Tingting Zou, Mei Wang, Wenjie Xiong, Wen Deng, Jing Wei, Jiangqing Yu, Chunbo Zhang, Huaijun Tu, Tingtao Chen

{"title":"Synbiotic Supplementation With Heyndrickxia coagulans TBC169 Improves Chronic Constipation in Middle-Aged and Elderly","authors":"Xiaoni Zhou, Canhui Guo, Gang Hu, Leiping Ding, Tingting Zou, Mei Wang, Wenjie Xiong, Wen Deng, Jing Wei, Jiangqing Yu, Chunbo Zhang, Huaijun Tu, Tingtao Chen","doi":"10.1002/biot.70250","DOIUrl":null,"url":null,"abstract":"<div>\n \n Background: Chronic constipation is prevalent in middle-aged and elderly individuals and can markedly impair quality of life and increase comorbidity risk. However, safe and effective therapies for this population remain limited because of age-related physiological changes, polypharmacy, and concerns about long-term medication use.\n Methods: We conducted a randomized, double-blind, controlled clinical trial enrolling 140 participants aged ≥45 years with chronic constipation to evaluate a synbiotic containing Heyndrickxia coagulans (H. coagulans) TBC169 plus dietary fibers as an adjunct intervention.\n Results: Compared with dietary fiber alone, the TBC169-based synbiotic significantly improved constipation outcomes, including increased weekly bowel movements (WBMs), higher Bristol stool scale (BSS) scores, and reduced Wexner and Patient Assessment of Constipation Quality of Life (PAC-QOL) scores. Post-intervention gut microbiota profiling showed higher Shannon and Faith_PD diversity indices and distinct community composition in the synbiotic group compared with the dietary-fiber control group, along with higher relative abundance of Blautia, Akkermansia, Faecalibacterium, and Bacillus and lower relative abundance of Collinsella. Because baseline faecal samples were not collected, these microbiota findings should be interpreted as exploratory between-group associations. Ecological analyses suggested enhanced microbial stability and metabolic potential, and correlations linked key taxa with clinical improvement. The intervention was well-tolerated, with only mild, transient adverse events.\n Conclusions: The synbiotic formulation containing H. coagulans TBC169 and dietary fiber-related components was well-tolerated and may improve constipation-related outcomes in middle-aged and elderly adults. Because the formulation contained both probiotic and fiber components, the observed effects should be attributed to the combined synbiotic product rather than to H. coagulans TBC169 alone.\n Trial Registration: Chinese Clinical Trial Registry (ChiCTR2400085844, http://www.chictr.org.cn/), registered on June 19, 2024.\n </div>","PeriodicalId":134,"journal":{"name":"Biotechnology Journal","volume":"21 6","pages":""},"PeriodicalIF":3.7000,"publicationDate":"2026-06-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biotechnology Journal","FirstCategoryId":"5","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/biot.70250","RegionNum":3,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"BIOCHEMICAL RESEARCH METHODS","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Chronic constipation is prevalent in middle-aged and elderly individuals and can markedly impair quality of life and increase comorbidity risk. However, safe and effective therapies for this population remain limited because of age-related physiological changes, polypharmacy, and concerns about long-term medication use.

Methods: We conducted a randomized, double-blind, controlled clinical trial enrolling 140 participants aged ≥45 years with chronic constipation to evaluate a synbiotic containing Heyndrickxia coagulans (H. coagulans) TBC169 plus dietary fibers as an adjunct intervention.

Results: Compared with dietary fiber alone, the TBC169-based synbiotic significantly improved constipation outcomes, including increased weekly bowel movements (WBMs), higher Bristol stool scale (BSS) scores, and reduced Wexner and Patient Assessment of Constipation Quality of Life (PAC-QOL) scores. Post-intervention gut microbiota profiling showed higher Shannon and Faith_PD diversity indices and distinct community composition in the synbiotic group compared with the dietary-fiber control group, along with higher relative abundance of Blautia, Akkermansia, Faecalibacterium, and Bacillus and lower relative abundance of Collinsella. Because baseline faecal samples were not collected, these microbiota findings should be interpreted as exploratory between-group associations. Ecological analyses suggested enhanced microbial stability and metabolic potential, and correlations linked key taxa with clinical improvement. The intervention was well-tolerated, with only mild, transient adverse events.

Conclusions: The synbiotic formulation containing H. coagulans TBC169 and dietary fiber-related components was well-tolerated and may improve constipation-related outcomes in middle-aged and elderly adults. Because the formulation contained both probiotic and fiber components, the observed effects should be attributed to the combined synbiotic product rather than to H. coagulans TBC169 alone.

Trial Registration: Chinese Clinical Trial Registry (ChiCTR2400085844, http://www.chictr.org.cn/), registered on June 19, 2024.

Abstract Image

查看原文本刊更多论文

加促凝剂TBC169改善中老年慢性便秘。

背景：慢性便秘在中老年人群中普遍存在，可显著影响生活质量并增加合并症的风险。然而，由于与年龄相关的生理变化、多种用药以及对长期用药的担忧，针对这一人群的安全有效的治疗方法仍然有限。方法：我们进行了一项随机、双盲、对照临床试验，纳入140名年龄≥45岁的慢性便秘患者，以评估含有海因drickxia凝血菌（H. coagulans） TBC169和膳食纤维的合成物作为辅助干预。结果：与单独使用膳食纤维相比，基于tbc169的益生菌显著改善了便秘结局，包括每周排便量（WBMs）增加，布里斯托大便量表（BSS）评分更高，Wexner和患者便秘生活质量评估（PAC-QOL）评分降低。干预后的肠道微生物群分析显示，与膳食纤维对照组相比，合成组的Shannon和Faith_PD多样性指数更高，群落组成明显，Blautia、Akkermansia、Faecalibacterium和Bacillus的相对丰度更高，Collinsella的相对丰度更低。由于没有收集基线粪便样本，这些微生物群的发现应被解释为探索性组间关联。生态分析表明微生物稳定性和代谢潜力增强，关键类群与临床改善相关。干预是耐受性良好的，只有轻微的，短暂的不良事件。结论：含有凝血凝杆菌TBC169和膳食纤维相关成分的合成制剂耐受性良好，可能改善中老年人便秘相关结局。由于该制剂同时含有益生菌和纤维成分，因此所观察到的效果应归功于联合合成产品，而不是单独的凝结芽孢杆菌TBC169。试验注册：中国临床试验注册中心（ChiCTR2400085844, http://www.chictr.org.cn/），于2024年6月19日注册。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Biotechnology Journal Biochemistry, Genetics and Molecular Biology-Molecular Medicine

CiteScore

8.90

自引率

2.10%

发文量

123

审稿时长

1.5 months

期刊介绍： Biotechnology Journal (2019 Journal Citation Reports: 3.543) is fully comprehensive in its scope and publishes strictly peer-reviewed papers covering novel aspects and methods in all areas of biotechnology. Some issues are devoted to a special topic, providing the latest information on the most crucial areas of research and technological advances. In addition to these special issues, the journal welcomes unsolicited submissions for primary research articles, such as Research Articles, Rapid Communications and Biotech Methods. BTJ also welcomes proposals of Review Articles - please send in a brief outline of the article and the senior author''s CV to the editorial office. BTJ promotes a special emphasis on: Systems Biotechnology Synthetic Biology and Metabolic Engineering Nanobiotechnology and Biomaterials Tissue engineering, Regenerative Medicine and Stem cells Gene Editing, Gene therapy and Immunotherapy Omics technologies Industrial Biotechnology, Biopharmaceuticals and Biocatalysis Bioprocess engineering and Downstream processing Plant Biotechnology Biosafety, Biotech Ethics, Science Communication Methods and Advances.